Laboratory of Neuroendocrinology, The Rockefeller University, New York, NY, USA.
CNS Neurol Disord Drug Targets. 2009 Dec;8(6):451-8. doi: 10.2174/187152709789824624.
The central endocannabinoid system is a neuroactive lipid signalling system in the brain which acts to control neurotransmitter release. The expression patterns of this system throughout limbic regions of the brain ideally situate it to exert regulatory control over emotional behaviour, mood and stress responsivity. A growing body of evidence unequivocally demonstrates that deficits in endocannabinoid signalling may result in depressive and anxiogenic behavioral responses, while pharmacological augmentation of endocannabinoid signalling can produce both antidepressive and anxiolytic behavioral responses. The aim of this review is to summarize current knowledge of the role of the endocannabinoid system in the etiology and treatment of mood and anxiety disorders, such as depression, anxiety and post-traumatic stress disorder. Collectively, both clinical and preclinical data argue that cannabinoid receptor signalling may be a realistic target in the development of a novel class of agent for the pharmacotherapy of mood and anxiety disorders.
中央内源性大麻素系统是大脑中的一种神经活性脂质信号系统，可控制神经递质的释放。该系统在大脑边缘区域的表达模式使其能够对情绪行为、情绪和应激反应进行调节控制。越来越多的证据明确表明，内源性大麻素信号传导的缺陷可能导致抑郁和焦虑行为反应，而内源性大麻素信号传导的药理学增强则可产生抗抑郁和抗焦虑行为反应。本综述的目的是总结内源性大麻素系统在抑郁、焦虑和创伤后应激障碍等心境和焦虑障碍的发病机制和治疗中的作用。总的来说，临床前和临床数据都表明，大麻素受体信号可能是开发新型心境和焦虑障碍药物治疗药物的一个有前途的靶点。
